 Complement Inactivator Proteins
"Complement Inactivator Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Serum proteins that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host. The complement system is tightly regulated by inactivators that accelerate the decay of intermediates and certain cell surface receptors.
| Descriptor ID |
D003169
|
| MeSH Number(s) |
D12.776.124.486.274.920
|
| Concept/Terms |
Complement Inactivator Proteins- Complement Inactivator Proteins
- Inactivator Proteins, Complement
- Proteins, Complement Inactivator
- Serum Complement Inactivators
- Complement Inactivators, Serum
- Inactivators, Serum Complement
- Complement Inactivating Proteins
- Inactivating Proteins, Complement
- Proteins, Complement Inactivating
|
Below are MeSH descriptors whose meaning is more general than "Complement Inactivator Proteins".
Below are MeSH descriptors whose meaning is more specific than "Complement Inactivator Proteins".
This graph shows the total number of publications written about "Complement Inactivator Proteins" by people in this website by year, and whether "Complement Inactivator Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 2 | 0 | 2 | | 1994 | 0 | 1 | 1 | | 1996 | 1 | 0 | 1 | | 1998 | 2 | 0 | 2 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 1 | 2 | | 2001 | 2 | 0 | 2 | | 2002 | 2 | 0 | 2 | | 2003 | 3 | 0 | 3 | | 2004 | 1 | 1 | 2 | | 2005 | 1 | 1 | 2 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Complement Inactivator Proteins" by people in Profiles.
-
Bomback AS, Appel GB, Gipson DS, Hladunewich MA, Lafayette R, Nester CM, Parikh SV, Smith RJH, Trachtman H, Heeger PS, Ram S, Rovin BH, Ali S, Arceneaux N, Ashoor I, Bailey-Wickins L, Barratt J, Beck L, Cattran DC, Cravedi P, Erkan E, Fervenza F, Frazer-Abel AA, Fremeaux-Bacchi V, Fuller L, Gbadegesin R, Hogan JJ, Kiryluk K, le Quintrec-Donnette M, Licht C, Mahan JD, Pickering MC, Quigg R, Rheault M, Ronco P, Sarwal MM, Sethna C, Spino C, Stegall M, Vivarelli M, Feldman DL, Thurman JM. Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Am J Kidney Dis. 2022 04; 79(4):570-581.
-
Bao L, Osawe I, Haas M, Quigg RJ. Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol. 2005 Aug 01; 175(3):1947-55.
-
He C, Imai M, Song H, Quigg RJ, Tomlinson S. Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9. J Immunol. 2005 May 01; 174(9):5750-7.
-
Mühlfeld AS, Segerer S, Hudkins K, Farr AG, Bao L, Kraus D, Holers VM, Quigg RJ, Alpers CE. Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis. Kidney Int. 2004 Apr; 65(4):1214-23.
-
Quigg RJ. Complement and autoimmune glomerular diseases. Curr Dir Autoimmun. 2004; 7:165-80.
-
Alexander JJ, Bao L, Jacob A, Kraus DM, Holers VM, Quigg RJ. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis. Biochim Biophys Acta. 2003 Nov 20; 1639(3):169-76.
-
Quigg RJ. Role of complement and complement regulatory proteins in glomerulonephritis. Springer Semin Immunopathol. 2003 May; 24(4):395-410.
-
Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM, Quigg RJ. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol. 2003 Mar; 14(3):670-9.
-
Quigg RJ. Use of complement inhibitors in tissue injury. Trends Mol Med. 2002 Sep; 8(9):430-6.
-
Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, Alexander JJ, Anderson RK, Culhane K, Holers VM, Quigg RJ. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol. 2002 Apr 01; 168(7):3601-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|